NASDAQ:AGRX Agile Therapeutics (AGRX) Stock Price, News & Analysis → $1,500 to $9,400 in one month? (A.I. Trade List) (From Prosper Trading Academy) (Ad) Free AGRX Stock Alerts $0.37 0.00 (0.00%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.3950-Day Range$0.27▼$0.6052-Week Range$0.20▼$4.06Volume9,075 shsAverage Volume27,529 shsMarket Capitalization$2.57 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Agile Therapeutics alerts: Email Address Agile Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside2,167.3% Upside$8.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment0.34Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.20 out of 5 stars 3.3 Analyst's Opinion Consensus RatingAgile Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAgile Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Agile Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AGRX. Previous Next 0.0 Dividend Strength Dividend YieldAgile Therapeutics does not currently pay a dividend.Dividend GrowthAgile Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agile Therapeutics is -1.59. Previous Next 1.9 News and Social Media Coverage News SentimentAgile Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Agile Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for AGRX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agile Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.50% of the stock of Agile Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.92% of the stock of Agile Therapeutics is held by institutions.Read more about Agile Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Agile Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agile Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Agile Therapeutics Stock (NASDAQ:AGRX)Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Read More AGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGRX Stock News HeadlinesMay 22, 2024 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Shares Pass Below 200 Day Moving Average of $1.21May 22, 2024 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Now Covered by Analysts at StockNews.comMay 16, 2024 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | investorplace.comAGRX Stock Earnings: Agile Therapeutics Misses EPS, Beats Revenue for Q1 2024May 15, 2024 | sfgate.comAgile Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | finance.yahoo.comAgile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | globenewswire.comAgile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 1, 2024 | finance.yahoo.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | seekingalpha.comAgile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | investorplace.comAGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023March 29, 2024 | finance.yahoo.comQ4 2023 Agile Therapeutics Inc Earnings CallMarch 28, 2024 | markets.businessinsider.comHere's what to expect from Agile Therapeutics's earnings reportMarch 28, 2024 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comAgile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate UpdateMarch 26, 2024 | msn.comWhy Agile Therapeutics (AGRX) Stock Is Down 60%March 26, 2024 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Announces Delisting from NasdaqMarch 25, 2024 | globenewswire.comAgile Therapeutics Announces Delisting from NasdaqMarch 23, 2024 | benzinga.comLatest News for Agile Therapeutics Stock (NASDAQ:AGRX)March 21, 2024 | markets.businessinsider.comAgile Therapeutics is about to announce its earnings — here's what to expectMarch 21, 2024 | benzinga.comAgile Therapeutics's Earnings: A PreviewMarch 21, 2024 | globenewswire.comCorrection - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024March 20, 2024 | globenewswire.comAgile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024March 13, 2024 | msn.comAgile Therapeutics stock soars on complete debt payoffMarch 13, 2024 | globenewswire.comAgile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan ExecutionFebruary 24, 2024 | investing.comAgile Therapeutics reduces warrant exercise priceSee More Headlines Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today5/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGRX CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,167.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,470,000.00 Net Margins-36.24% Pretax Margin-36.24% Return on EquityN/A Return on Assets-147.37% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.38 Sales & Book Value Annual Sales$19.59 million Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book Value($1.51) per share Price / Book-0.25Miscellaneous Outstanding Shares6,860,000Free Float6,822,000Market Cap$2.57 million OptionableNot Optionable Beta1.25 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Alfred F. Altomari (Age 65)Chairman, President & CEO Comp: $646.53kMr. Scott M. Coiante (Age 57)CFO, Senior VP & Treasurer Comp: $436.91kMr. Geoffrey P. Gilmore (Age 58)Senior VP & Chief Administrative Officer Comp: $494.85kDr. Paul Korner M.B.A. (Age 58)M.D., Senior VP & Chief Medical Officer Comp: $494.6kMr. Robert G. Conway M.E. (Age 67)Senior VP and Chief Corporate Planning & Supply Chain Officer Comp: $444.11kMs. Amy Welsh (Age 53)Senior VP & Chief Commercial Officer More ExecutivesKey CompetitorsBiophytisNASDAQ:BPTSYCNS PharmaceuticalsNASDAQ:CNSPBiophytisNASDAQ:BPTSAridis PharmaceuticalsNASDAQ:ARDSAraviveNASDAQ:ARAVView All Competitors AGRX Stock Analysis - Frequently Asked Questions Should I buy or sell Agile Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks. What is Agile Therapeutics' stock price target for 2024? 2 brokerages have issued 12 month target prices for Agile Therapeutics' stock. Their AGRX share price targets range from $5.00 to $12.00. On average, they expect the company's share price to reach $8.50 in the next year. This suggests a possible upside of 2,167.3% from the stock's current price. View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts. How have AGRX shares performed in 2024? Agile Therapeutics' stock was trading at $1.95 on January 1st, 2024. Since then, AGRX stock has decreased by 80.8% and is now trading at $0.3749. View the best growth stocks for 2024 here. How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) released its quarterly earnings results on Wednesday, May, 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The specialty pharmaceutical company had revenue of $5.72 million for the quarter. When did Agile Therapeutics' stock split? Agile Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX). How do I buy shares of Agile Therapeutics? Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AGRX) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWARNING about the death of the U.S. dollar…Colonial Metals$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBiden replacement revealed?Paradigm PressNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTradeThe only AI company to buyPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.